CRMD - CorMedix Inc Debt to Book Capitalization Ratio

Graphic logo of CorMedix Inc (CRMD)

CorMedix Inc. (CRMD) is protected by unique patents for catheter antiseptics, which blocks competitors under strict FDA oversight. This chart reflects a current share price of 0.31, while the company is betting on organic growth and the search for distribution partners. The business remains independent of economic cycles, relying instead on certification cycles for dialysis infection prevention tools.

CRMD (CorMedix Therapeutics) Debt to Book Value history from 07/04/2022 to 10/28/2026

Metric breakdowns and analytics for CorMedix Inc (CRMD)

- price and consensus price forecast:
Stock Price CorMedix Inc.|CRMD - Analyst Consensus Forecast
- market capitalization data:
Market Value CorMedix Therapeutics|CRMD - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share CorMedix|CRMD - Company Net Assets|Market Capitalization to Book Value Ratio cormedix.com|CRMD - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio CorMedix Inc.|CRMD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital CorMedix Corp|CRMD - Company Total Debt Obligations|Debt to Book Capitalization Ratio CorMedix Therapeutics|CRMD - Company Long-Term Indebtedness|Company Short-Term Debts CorMedix
Summary company analytics:CRMD - CorMedix Inc.
Core merchandise of CorMedix Inc

Investors are assessing the potential of CorMedix Inc. (CRMD) through the lens of debt load, where the debt-to-equity ratio determines the business's financial stability. By analyzing the current debt-to-equity ratio, one can understand how effectively strategic alliances with dialysis centers are funded through leverage, which characterizes the company as a high-risk asset with significant leverage.

Competitors of CorMedix Inc.

Debts to Book Capitalization SMMT (Summit Therapeutics)|modernatx.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Vaxcyte (PCVX)|TARS: Debt to Net Assets Ratio|MCRB (Seres) - Debt to Book Capitalization Ratio|Spero Pharma (SPRO) - Debt to Book Value|SCYX (SCYNEXIS Inc) - Debts to Book Capitalization|Debts to Book Capitalization AN2 Bio (ANTX)|PolyPid Ltd. (PYPD) - Debt to Book Value|Debt to Net Assets Ratio LakeShore Biopharma Co., Ltd. (LSB)|Debts to Book Capitalization ITRM|BiomX Inc - Debts to Net Assets|BioPharma Bio (SNGX) - Debt to Book Capitalization Ratio|SXTP - Debt to Book Value Ratio|Debts to Book Capitalization Oragenics (OGEN)|Onconetix Inc (ONCO) - Debts to Book Capitalization Ratio|Debts to Book Capitalization OPGN (OpGen Corp)